Buy, Sell or Hold: Johnson & Johnson (JNJ-N) — Stock Predictions at Stockchase

skip to content

NYSE:JNJ

181.09

1.63 (0.91%) 1d

Showing 1 to 15 of 522 entries

«
‹
1
2
3
4
5
›
»

Next Page

TOP PICK

A traditional recession-proof company. Model price of $171 or so, a 4% overvaluation. Going to split off vaccine division, which is bullish for the stock. Not much upside, but you're looking for companies to get you through a recession deeper than a lot of people realize. Yield is 2.51%. (Analysts’ price target is $190.39)

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Mar 03/21, Up 14%) Pharmaceutical sector has remained strong even with tech selloff. Spinning out consumer side of the business which has provided catalyst for return on stock. Current stock price presenting good buying opportunity. Will continue to buy and hold shares in company.

biotechnology / pharmaceutical

COMMENT

Reported a strong last quarter. He was furious when shares fell down. This comes down to market fears, not JNJ itself.

biotechnology / pharmaceutical

BUY

Tuesday morning they reported an inline quarter, except the previously struggling medtech division which is now soaring. JNJ said that after Covid that surgeries would return, so medical device sales would bounce back--and they did. Has a fine balance sheet and does share buybacks. JNJ returns wealth to shareholders.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Mar 30/20, Up 39.2%) Still likes it. Model price of $191.71, still upside of about 10%. Would have been a Top Pick today, but chose a fresh idea instead. In the process of splitting between vaccines and consumer so keep an eye on it, as you might make some money on the transaction.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Mar 16/21, Up 10%) A stable healthcare name. AAA balance sheet. Has owned this for years. Has raised its dividend for 6 decades. Pays 2.5%. Their pharma business is strong. A return to surgeries will boost their medical devices division. They will spin off their consumer health division, a small part of their business. She likes healthcare for its long-term growth. They have a good pipeline of pharma drugs coming.

biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In

PAST TOP PICK

(A Top Pick Dec 02/21, Up 1.9%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with JNJ has triggered its stop at $160. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 4%, when combined with the previous buy recommendation.

biotechnology / pharmaceutical

Unlock Panic-Proof Portfolio and Top Stock Picks

Become a member Or, Sign In

PAST TOP PICK

(A Top Pick Dec 02/21, Up 10.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with JNJ is progressing well. We now recommend trailing up the stop (from $147) to $160.

biotechnology / pharmaceutical

BUY

Healthcare has been tough. JNJ has done better than the group. Rising RSI since November. Yield is 2.5%, with 6-6% dividend growth. Pretty attractive. Sector won't provide a huge tailwind, but a good journeyman position.

biotechnology / pharmaceutical

BUY on WEAKNESS

Can vaccine business overcome litigation risk? Doesn't think so. PZE is going to be the dominant player. JNJ is the elephant in the room in large cap healthcare. Really well diversified across medical devices. Valuation a bit high, fine to hold. Defensive go-to name when the market's concerned. If there's a shift to growth in Q1, you may get a chance to pick this up lower. Spinoff of lower growth consumer business will let them be more focused.

biotechnology / pharmaceutical

BUY

Russia fomenting a war with Ukraine will likely see oil prices explode higher, based on historic precedent. Industries and stocks that will rise if a war happens (and nobody wants one outside Russia) are oil, consumer staples, drug companies like Procter & Gamble or JNJ. Also defence stocks like Raytheon which reports tomorrow or Lockheed are buys.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Jan 10/20, Up 25%) A great buy here. Model price of $214.71, 25% upside. Yield is 2.44%.

biotechnology / pharmaceutical

PARTIAL BUY

He's surprised--JNJ will spin-off its consumer health as a separate company to leave behind a best-of-breed drug and medical device business. He's a big fan of JNJ. It could take 1.5-2 years for this break-up to play out, so be patient. JNJ has one of the best drug businesses, but it's buried within a larger business while medical devices is growing strong. JNJ trades at 16x 2022 earnings, much lower than its peers. Has a strong balance sheet. Pays a 2.5% dividend yield. Share could rise as more details of the break-out come. Their Covid wasn't doesn't seem effective now.

biotechnology / pharmaceutical

BUY

A number of different business units with potential. Likes Johnson & Johnson as it is a well run company. Very inexpensive stock with free cash flow yield is ~5% and forward P/E ratio at 16x. Executive stock compensation is reason why buybacks aren't reducing share count. Share buybacks are popular because managements can understand own business model better that alternative use of capital.

biotechnology / pharmaceutical

COMMENT

Owns Johnson & Johnson. Three divisions which are very strong. Spinning out personal care division. Good balance sheet and has increased dividend every year for 50 years. Elective surgeries increasing post Covid-19. Believes will continue to be great company. Bullish on healthcare & pharmaceutical industry.

biotechnology / pharmaceutical

Showing 1 to 15 of 522 entries

«
‹
1
2
3
4
5
›
»

Next Page

Johnson & Johnson(JNJ-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 30

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 32

Stockchase rating for Johnson & Johnson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Johnson & Johnson(JNJ-N) Frequently Asked Questions

What is Johnson & Johnson stock symbol?

Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N

Is Johnson & Johnson a buy or a sell?

In the last year, 32 stock analysts published opinions about JNJ-N. 30 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Johnson & Johnson.

Is Johnson & Johnson a good investment or a top pick?

Johnson & Johnson was recommended as a Top Pick by on . Read the latest stock experts ratings for Johnson & Johnson.

Why is Johnson & Johnson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Johnson & Johnson worth watching?

32 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.

What is Johnson & Johnson stock price?

On 2022-05-27, Johnson & Johnson (JNJ-N) stock closed at a price of $181.09.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.